Zosano Pharma Corp
F:0ZPN
Balance Sheet
Balance Sheet Decomposition
Zosano Pharma Corp
Zosano Pharma Corp
Balance Sheet
Zosano Pharma Corp
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5
|
6
|
1
|
7
|
15
|
12
|
9
|
6
|
35
|
11
|
|
| Cash Equivalents |
5
|
6
|
1
|
7
|
15
|
12
|
9
|
6
|
35
|
11
|
|
| Short-Term Investments |
0
|
0
|
0
|
30
|
0
|
0
|
14
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
1
|
0
|
0
|
|
| Total Current Assets |
6
|
10
|
2
|
37
|
15
|
13
|
23
|
7
|
36
|
12
|
|
| PP&E Net |
1
|
12
|
10
|
8
|
5
|
4
|
12
|
30
|
36
|
36
|
|
| PP&E Gross |
1
|
0
|
10
|
8
|
0
|
0
|
12
|
30
|
36
|
36
|
|
| Accumulated Depreciation |
2
|
0
|
20
|
22
|
0
|
0
|
26
|
27
|
28
|
30
|
|
| Long-Term Investments |
12
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
2
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Assets |
20
N/A
|
22
+12%
|
13
-40%
|
45
+240%
|
21
-54%
|
18
-14%
|
36
+99%
|
38
+5%
|
72
+91%
|
48
-33%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
3
|
1
|
1
|
1
|
2
|
4
|
4
|
2
|
2
|
|
| Accrued Liabilities |
0
|
3
|
3
|
2
|
2
|
2
|
5
|
7
|
7
|
5
|
|
| Short-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
3
|
9
|
3
|
6
|
7
|
2
|
5
|
6
|
4
|
|
| Other Current Liabilities |
3
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
4
|
12
|
13
|
7
|
10
|
10
|
11
|
16
|
15
|
11
|
|
| Long-Term Debt |
9
|
10
|
13
|
12
|
7
|
0
|
5
|
6
|
5
|
1
|
|
| Other Liabilities |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
6
|
5
|
3
|
|
| Total Liabilities |
14
N/A
|
22
+59%
|
27
+24%
|
19
-30%
|
16
-13%
|
11
-33%
|
17
+56%
|
28
+66%
|
25
-13%
|
15
-37%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
119
|
124
|
138
|
167
|
197
|
226
|
261
|
299
|
332
|
362
|
|
| Additional Paid In Capital |
125
|
125
|
125
|
193
|
201
|
233
|
280
|
308
|
380
|
395
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
6
N/A
|
0
-92%
|
13
N/A
|
27
N/A
|
4
-83%
|
7
+57%
|
19
+165%
|
9
-50%
|
48
+406%
|
33
-31%
|
|
| Total Liabilities & Equity |
20
N/A
|
22
+12%
|
13
-40%
|
45
+240%
|
21
-54%
|
18
-14%
|
36
+99%
|
38
+5%
|
72
+91%
|
48
-33%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
1
|
0
|
1
|
1
|
2
|
12
|
24
|
102
|
3
|
|